TOP TIERMARKET NEWSWIRE
News & sentiment

AKEBIA THERAPEUTICS (AKBA) — News & AI sentiment

AKEBIA THERAPEUTICS (AKBA) news roundup. 1 story in the past week, 9 over 30 days. Average 30-day sentiment is 51/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
1
avg sentiment 34/100
30d stories
9
avg sentiment 51/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

AKBA news in the last 24 hours, 7 days, 30 days and 90 days

How much AKBA coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowAKBA storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days134/100AKBA headlines →
Last 30 days951/100AKBA headlines →
Last 90 days2754/100AKBA headlines →

Latest stories on AKBA

5d ago
Oct 14
Oct 14
Oct 7
Oct 7
Oct 6
Oct 6
Oct 1
Oct 1
Sep 15
Sep 14
Sep 14
Sep 14
Sep 8
Sep 1
Sep 1
Sep 1
Sep 1
Sep 1
Aug 7
H.C. Wainwright reiterates Buy on Akebia stock, $6 target
Investing.com Analyst Ratings61 · neutralanalyst
Aug 6
Aug 6
Aug 6
Aug 5
Aug 5
Open AKBA in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →